AMGN- Amgen Inc.
Healthcare · Drug Manufacturers - General
Price & Performance
Performance
Analysis & Verdict
Analyst Ratings
HoldWall Street consensus from 29 analysts
12-Month Price Target
$388.03
Based on analyst estimates; price targets are opinions, not guarantees.
Fair Value Estimates
Current price: $377.35
Graham Number
√(22.5 × EPS × Book Value)
$88.53
Benjamin Graham's intrinsic value formula. Assumes a fair stock trades at no more than 22.5× the product of EPS and book value per share.
Bazin Ceiling Price
Avg. Annual DPS (5Y) ÷ 6%
$139.47
Décio Bazin's dividend-based ceiling. The max price you should pay so that dividends alone deliver at least 6% annual yield on your cost basis.
These are simplified estimates. Not financial advice.
Buy & Hold Checklist
Quality criteria for long-term holding
9/10
90% score
Pays dividends
15Y hist.15+ years of dividend history
Dividend consistency (5Y+)
15 yrsUninterrupted dividend payments for at least 5 years
ROE above 10%
91.5%Return on equity - measures how efficiently capital is used
Positive profit margin
23.0%Net profit margin must be positive - company earns more than it spends
Revenue growth (annual)
+9.5%Annual revenue must be growing compared to the prior year
Earnings growth (annual)
+64.9%Annual earnings must be growing compared to the prior year
Debt/Equity below 2×
490.28×Low financial leverage reduces risk of distress
Current ratio above 1
1.37×Short-term assets must cover short-term liabilities
Daily liquidity above $5M
$1.0B/dayHigh trading volume ensures easy entry and exit
Dividend yield above 0%
2.64%Stock must distribute income to shareholders
Financials
Revenue & Results
Key Statistics
Earnings
Next Earnings
Nov 3, 2026
51
days
EPS (TTM)
$16.11
P/E (TTM)
23.4
Fwd P/E
15.5
SEC Filings & Reported Financials
Earnings History
SEC EDGAR · official filings
SEC Filings
Official EDGAR documents
Insider Transactions
SEC Form 4 · officers, directors & 10% owners
Dividends & Income
Dividends
Current DY
2.64%
5Y Avg Annual
$8.4720
Last Payment
$2.5200
Ex-Date
08/21/2026
Annual dividends paid per share
| Ex-Date | Payment | Amount | Est. DY |
|---|---|---|---|
Latest08/21/2026 | 09/11/2026 | $2.5200 | 2.67% |
05/15/2026 | 06/05/2026 | $2.5200 | 2.67% |
02/13/2026 | 03/06/2026 | $2.5200 | 2.67% |
11/21/2025 | 12/12/2025 | $2.3800 | 2.52% |
08/22/2025 | 09/12/2025 | $2.3800 | 2.52% |
05/16/2025 | 06/06/2025 | $2.3800 | 2.52% |
02/14/2025 | 03/07/2025 | $2.3800 | 2.52% |
11/18/2024 | 12/09/2024 | $2.2500 | 2.39% |
Magic Number
Shares needed to self-fund your next purchase
$377.35
Price
$2.5200
Last div. (quarterly)
150
shares
Own 150 AMGN shares ($56,602.50) and each quarterly dividend pays for 1 new share - the snowball runs on its own.
Investment target
$56,602.50
New shares / year
+4 shares
Dividend Calculator
2.67% yieldEstimate AMGN dividend income at the current rate.
Per year
$267.13
Per month
$22.26
≈ 26.5 shares at $10.08/share a year. Estimate only - dividends can be cut or raised.
Tools & Simulators
AMGN vs Peers, Indexes & Commodities
?Click a card below to plot it on the chart
Loading history…
Parameters
Final value
$426,404.61
Total invested
$130,000.00
Total interest
$296,404.61
Balance over time
Period breakdown
| Period | Balance | Invested | Interest |
|---|---|---|---|
| Start | $10,000.00 | $10,000.00 | $0.00 |
| Year 1 | $17,270.27 | $16,000.00 | $1,270.27 |
| Year 2 | $25,267.56 | $22,000.00 | $3,267.56 |
| Year 3 | $34,064.59 | $28,000.00 | $6,064.59 |
| Year 4 | $43,741.32 | $34,000.00 | $9,741.32 |
| Year 5 | $54,385.72 | $40,000.00 | $14,385.72 |
| Year 6 | $66,094.55 | $46,000.00 | $20,094.55 |
| Year 7 | $78,974.28 | $52,000.00 | $26,974.28 |
| Year 8 | $93,141.97 | $58,000.00 | $35,141.97 |
| Year 9 | $108,726.44 | $64,000.00 | $44,726.44 |
| Year 10 | $125,869.35 | $70,000.00 | $55,869.35 |
| Year 11 | $144,726.56 | $76,000.00 | $68,726.56 |
| Year 12 | $165,469.48 | $82,000.00 | $83,469.48 |
| Year 13 | $188,286.70 | $88,000.00 | $100,286.70 |
| Year 14 | $213,385.63 | $94,000.00 | $119,385.63 |
| Year 15 | $240,994.47 | $100,000.00 | $140,994.47 |
| Year 16 | $271,364.18 | $106,000.00 | $165,364.18 |
| Year 17 | $304,770.87 | $112,000.00 | $192,770.87 |
| Year 18 | $341,518.22 | $118,000.00 | $223,518.22 |
| Year 19 | $381,940.31 | $124,000.00 | $257,940.31 |
| Year 20 | $426,404.61 | $130,000.00 | $296,404.61 |
What is compound interest?
Compound interest means that the interest you earn in one period is added to your principal, so in the next period you earn interest on a larger base. This creates exponential growth: the longer your time horizon, the more dramatic the effect.
Which rate should I use?
The S&P 500 has historically returned ~10%/year before inflation over long periods - use this for an all-equity US index fund scenario. A balanced growth portfolio (stocks + bonds) is closer to 7%. High-yield savings accounts (HYSA) are currently paying around 4-5% with FDIC insurance and zero market risk. Bonds historically return ~4% annualized.
Formula used
FV = PV × (1+r)^n + PMT × ((1+r)^n − 1) / rwhere r is the monthly rate, n is the number of months, PV is the initial investment, and PMT is the monthly contribution. Annual rates are converted to monthly viar = (1 + annual%)^(1/12) − 1.
For educational purposes only. Not financial advice. Past returns do not guarantee future results.
Discussion
Sign in to join the discussionSign inLoading…
Discover
Related Assets
Healthcare
Related Articles
About Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Sector
Healthcare
Industry
Drug Manufacturers - General
Location
Thousand Oaks, United States
Employees
31,500
Stock Market ROI Pro
All features, zero ads- web & app
Unlock every feature, ad-free, across our website and iOS app.
Amgen Inc. (AMGN) stock trades at $377.35, down 1.34% on the day. With a market capitalization of $204.01 billion, AMGN is a mega-cap healthcare stock. It trades at a price-to-earnings (P/E) ratio of 23.4, a forward P/E of 15.5 and earnings per share (EPS) of $16.11. Over the most recent period the company reported 10% year-over-year revenue growth and a net profit margin of 23.0%. Below you'll find AMGN's full fundamentals, fair-value estimates, dividend history, earnings and our buy, hold or avoid verdict for 2026.
AMGN - Frequently Asked Questions
Is Amgen Inc. (AMGN) a good stock to buy in 2026?
Amgen Inc. (AMGN) shows strengths such as a strong 23% net margin and a 91% return on equity, while risks include high leverage (debt/equity of 490.3). Whether AMGN is a good buy in 2026 depends on your time horizon and risk tolerance - review the full bull case, bear case and fair-value estimates above. This is informational analysis, not financial advice.
What is AMGN's stock price today?
Amgen Inc. (AMGN) trades at $377.35, down 1.34% on the session. Prices on this page update throughout the trading day.
Does AMGN pay a dividend?
Yes. Amgen Inc. pays an annual dividend of $10.08 per share, a dividend yield of 2.64%. The most recent ex-dividend date was August 21, 2026. Its payout ratio is about 61% of earnings.
Is AMGN overvalued?
With a P/E ratio of 23.4×, AMGN trades at a roughly market-average valuation for the healthcare sector. Its PEG ratio is 1.88. See the Fair Value Estimates section above for Graham Number and dividend-based price targets.
What is AMGN's market cap?
Amgen Inc. (AMGN) has a market capitalization of $204.01 billion, classifying it as a mega-cap stock in the Healthcare sector.
Disclaimer: This page - including any buy/hold/avoid view, fair value or price estimate - is generated from market data for informational and educational purposes only and does not constitute financial, investment or trading advice. Data may be delayed or inaccurate. Always do your own research and consult a licensed financial advisor before making any investment decision.